Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 2/20 | 0.36 |
| ▸ | CCR5 | P51681 | 2/20 | 0.36 |
| ▸ | CCR8 | P51685 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 3/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BCL6 | P41182 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29698775 | 0.81 | CCR1 (0.34) | CCR1CCR5CCR8PARP1MAPT | |
| SCHEMBL1073946 | 0.81 | CCR1 (0.52) | CCR1CCR5CCR8PARP1MAPT | |
| SCHEMBL31058344 | 0.81 | CCR1 (0.52) | CCR1CCR5CCR8PARP1MAPT | |
| SCHEMBL4157022 | 0.77 | SMN1; SMN2 (0.42) | ABCG2PARP1MAPTSYKMEN1 | |
| SCHEMBL29801578 | 0.77 | TET2 (0.44) | ABCG2CCR1CCR5CCR8TET2 | |
| SCHEMBL12483271 | 0.77 | ABCG2 (0.40) | ABCG2CCR1CCR5CCR8MAP4K4 | |
| SCHEMBL25519639 | 0.77 | CCR1 (0.67) | ABCG2CCR1CCR5CCR8PARP1 | |
| SCHEMBL12483903 | 0.77 | TET2 (0.44) | ABCG2CCR1CCR5CCR8TET2 | |
| SCHEMBL28088161 | 0.77 | ABCG2 (0.37) | ABCG2CCR1CCR5CCR8 | |
| SCHEMBL28012715 | 0.77 | ABCG2 (0.37) | ABCG2CCR1CCR5CCR8TET2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210387964-A1 | HETEROARYLAMINOQUINOLINES AND ANALOGUES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-16 | — | — | US | disclosed |
| CN-112888682-A | Heteroaryl aminoquinolines and analogs | 拜耳公司 | 2021-06-01 | — | — | CN | disclosed |
| WO-2020079167-A1 | HETEROARYLAMINOQUINOLINES AND ANALOGUES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-04-23 | — | — | WO | disclosed |
| CN-105906563-B | The synthetic method of 7,8- difluoro-quinoline -3- formic acid | 苏州康润医药有限公司 | 2019-01-22 | — | — | CN | disclosed |
| CN-105906563-A | Synthesis method of 7, 8-difluoroquinoline-3-formic acid | 苏州康润医药有限公司 | 2016-08-31 | — | — | CN | disclosed |
| CN-105906563-A | Synthesis method of 7, 8-difluoroquinoline-3-formic acid | 苏州康润医药有限公司 | 2016-08-31 | — | — | CN | disclosed |
| CN-104447543-B | Synthesis method of 3-amino-7, 8-difluoroquinoline and intermediate thereof | 苏州康润医药有限公司 | 2016-08-24 | — | — | CN | disclosed |
| CN-104447543-B | Synthesis method of 3-amino-7, 8-difluoroquinoline and intermediate thereof | 苏州康润医药有限公司 | 2016-08-24 | — | — | CN | disclosed |
| CN-104447543-A | Synthesis method of 3-amino-7, 8-difluoroquinoline and intermediate thereof | SUZHOU KANGRUN PHARMACEUTICALS INC | 2015-03-25 | — | — | CN | disclosed |
| CN-104447543-A | Synthesis method of 3-amino-7, 8-difluoroquinoline and intermediate thereof | SUZHOU KANGRUN PHARMACEUTICALS INC | 2015-03-25 | — | — | CN | disclosed |
| CN-104447543-A | Synthesis method of 3-amino-7, 8-difluoroquinoline and intermediate thereof | SUZHOU KANGRUN PHARMACEUTICALS INC | 2015-03-25 | — | — | CN | disclosed |
| EP-1189903-B1 | NOVEL BENZO[F]NAPHTHYRIDINE, PREPARATION AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2003-05-28 | — | — | EP | disclosed |
| US-6566362-B2 | Use as topical antibiotics | AVENTIS PHARMA S.A. (FR) | 2003-05-20 | — | — | US | disclosed |
| US-20020137741-A1 | Benzo[f]naphthyridine derivatives, their preparation and compositions containing them | AVENTIS PHARMA S.A. (FR) | 2002-09-26 | — | — | US | disclosed |
| EP-1189903-A1 | NOVEL BENZO F]NAPHTHYRIDINE, PREPARATION AND COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001002396-A1 | NOVEL BENZO[F]NAPHTHYRIDINE, PREPARATION AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137741-A1 | Benzo[f]naphthyridine derivatives, their preparation and compositions containing them | KCNQ2, KCNQ1, KCNQ4 | ABCG2 148/4885CCR1 4877/4885CCR5 4740/4885 |
| US-20210387964-A1 | HETEROARYLAMINOQUINOLINES AND ANALOGUES | PIK3C3, ERG28, CBR3 | ABCG2 258/4885CCR1 4678/4885CCR5 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.